DOC241220C25000
- 0.05
- +0.01+25.00%
Healthpeak Properties Newsroom
Citigroup Adjusts Price Target on Healthpeak Properties to $23 From $22, Maintains Neutral Rating
Mizuho Securities Maintains Healthpeak Properties(DOC.US) With Buy Rating
Strategic Growth and Valuation Justify Buy Rating for Healthpeak Properties
Healthpeak Properties Is Maintained at Outperform by RBC Capital
Healthpeak Properties Analyst Ratings
Analysts Offer Insights on Real Estate Companies: VICI Properties (VICI) and Healthpeak Properties (DOC)
RBC Raises Price Target on Healthpeak Properties to $26 From $25
Baird Maintains Healthpeak Properties(DOC.US) With Buy Rating, Raises Target Price to $25
Healthpeak Properties Is Maintained at Outperform by Baird
Healthpeak Properties Analyst Ratings
Baird Maintains Healthpeak Properties(DOC.US) With Buy Rating, Cuts Target Price to $25
KeyBanc Maintains Healthpeak Properties(DOC.US) With Hold Rating
Mizuho Securities Maintains Healthpeak Properties(DOC.US) With Buy Rating
Evercore Maintains Healthpeak Properties(DOC.US) With Buy Rating, Maintains Target Price $26
Healthpeak Properties (DOC) Receives a Buy From Evercore ISI
Scotiabank Maintains Healthpeak Properties(DOC.US) With Buy Rating, Maintains Target Price $24
Analysts Offer Insights on Real Estate Companies: Healthpeak Properties (DOC) and Cousins Properties (CUZ)
Morgan Stanley Maintains Healthpeak Properties(DOC.US) With Hold Rating, Maintains Target Price $23.5
BMO Capital Maintains Healthpeak Properties(DOC.US) With Buy Rating, Raises Target Price to $26
Healthpeak Properties: Strong Q3 2024 Earnings and Positive Financial Outlook Justify Buy Rating